Volume 3, Number 2—June 1997
Synopsis
Hantaviruses: A Global Disease Problem
Connie Schmaljohn*
and Brian Hjelle
and Brian Hjelle
Table 2
Distinguishing clinical characteristics for HFRS and HPS
| Disease | Pathogens | Distinguishing Characteristics* |
|---|---|---|
| HFRS (moderate-severe) Death rate 1%-15% | HTN, SEO, DOB | hemorrhage +++ azotemia/ proteinuria +++/++++ pulmonary capillary leak +/++ myositis +/+++ conjunctival injection ++/++++ eye pain/myopia ++/++++ |
| HFRS (mild) Death rate <1% | PUU | hemorrhage + azotemia/ proteinuria +/++++ pulmonary capillary leak -/+ myositis + conjunctival injection + eye pain/myopia ++/++++ |
| HPS (prototype) Death rate >40% | SN, NY | hemorrhage + zotemia/ proteinuria + pulmonary capillary leak ++++ myositis - conjunctival injection -/+ eye pain/myopia - |
| HPS (renal variant) Death rate>40% | BAY, BCC, Andes | hemorrhage + azotemia/ proteinuria ++/+++ pulmonary capillary leak +++/++++ myositis ++/++++ conjunctival injection -/++ eye pain/myopia - |
*Minimum/maximum occurrence of the characteristic: - rarely reported;
+ infrequent or mild manifestation; ++, +++, ++++ more frequent and severe manifestation.
Page created: December 21, 2010
Page updated: December 21, 2010
Page reviewed: December 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.